AG真人官方

STOCK TITAN
  1. Home
  2. News
  3. SSII
  4. SS Innovations Reports First Quarter 2025 Financial Results

SS Innovations Reports First Quarter 2025 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
earnings
Rhea-AI Summary
SS Innovations (NASDAQ: SSII) reported strong Q1 2025 financial results with record quarterly revenue of $5.1 million, up 40.8% year-over-year. The growth was driven by increased sales of their SSi Mantra 3 surgical robotic system. Key highlights include: - 15 new system installations (66.7% increase YoY) - Gross margin expanded to 21.23% - Net loss improved to $5.7 million ($0.03/share) vs $9.8 million ($0.06/share) in Q1 2024 - Cumulative installed base reached 78 units with 3,568 total surgeries performed - Cash position of $15.9 million with zero long-term debt The company achieved a significant milestone with its Nasdaq uplisting in April 2025 and plans to submit a De Novo FDA application for SSi Mantra 3 by July 2025, while pursuing EU CE Mark approval by late 2025.
SS Innovations (NASDAQ: SSII) ha riportato solidi risultati finanziari nel primo trimestre 2025, con un fatturato trimestrale record di 5,1 milioni di dollari, in crescita del 40,8% rispetto all'anno precedente. La crescita 猫 stata trainata dall'aumento delle vendite del sistema chirurgico robotico SSi Mantra 3. I punti salienti includono:
  • 15 nuove installazioni di sistema (aumento del 66,7% su base annua)
  • Margine lordo aumentato al 21,23%
  • Perdita netta migliorata a 5,7 milioni di dollari (0,03 dollari per azione) rispetto ai 9,8 milioni (0,06 dollari per azione) nel primo trimestre 2024
  • Base installata cumulativa raggiunta a 78 unit脿 con 3.568 interventi totali eseguiti
  • Posizione di cassa di 15,9 milioni di dollari senza debito a lungo termine
La societ脿 ha raggiunto un traguardo importante con la quotazione al Nasdaq nell'aprile 2025 e prevede di presentare una domanda De Novo alla FDA per SSi Mantra 3 entro luglio 2025, mentre punta ad ottenere l'approvazione CE per l'UE entro la fine del 2025.
SS Innovations (NASDAQ: SSII) report贸 s贸lidos resultados financieros en el primer trimestre de 2025, con un ingreso trimestral r茅cord de 5,1 millones de d贸lares, un aumento del 40,8% interanual. El crecimiento fue impulsado por el incremento en las ventas de su sistema quir煤rgico rob贸tico SSi Mantra 3. Los aspectos destacados incluyen:
  • 15 nuevas instalaciones del sistema (aumento del 66,7% interanual)
  • Margen bruto expandido al 21,23%
  • P茅rdida neta mejorada a 5,7 millones de d贸lares (0,03 d贸lares por acci贸n) frente a 9,8 millones (0,06 d贸lares por acci贸n) en el primer trimestre de 2024
  • Base instalada acumulada alcanz贸 78 unidades con 3.568 cirug铆as totales realizadas
  • Posici贸n de efectivo de 15,9 millones de d贸lares sin deuda a largo plazo
La compa帽铆a logr贸 un hito significativo con su listado en Nasdaq en abril de 2025 y planea presentar una solicitud De Novo a la FDA para el SSi Mantra 3 antes de julio de 2025, mientras busca la aprobaci贸n del marcado CE en la UE para finales de 2025.
SS Innovations (NASDAQ: SSII)電� 2025雲� 1攵勱赴鞐� 臧曤牓頃� 鞛 鞁れ爜鞚� 氤搓碃頄堨溂氅�, 攵勱赴氤� 毵れ稖鞚� 510毵� 雼煬搿� 靷儊 斓滉碃毳� 旮半頃橂┌ 鞝勲厔 霃欔赴 雽�牍� 40.8% 歃濌皜頄堨姷雼堧嫟. 鞚� 靹膘灔鞚� SSi Mantra 3 靾橃垹鞖� 搿滊磭 鞁滌姢韰� 韺愲Г 歃濌皜鞐� 頌橃瀰鞚� 瓴冹瀰雼堧嫟. 欤检殧 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
  • 15雽�鞚� 鞁犼窚 鞁滌姢韰� 靹れ箻 (鞝勲厔 雽�牍� 66.7% 歃濌皜)
  • 齑� 鞚挫澋毳犾澊 21.23%搿� 頇曤寑
  • 靾滌啇鞁れ澊 570毵� 雼煬(欤茧嫻 0.03雼煬)搿� 臧滌劆, 2024雲� 1攵勱赴 980毵� 雼煬(欤茧嫻 0.06雼煬) 雽�牍� 臧愳唽
  • 雸勳爜 靹れ箻 旮半皹 78雽�, 齑� 3,568瓯挫潣 靾橃垹 靾橅枆
  • 順勱笀 氤挫湢鞎� 1,590毵� 雼煬, 鞛リ赴 攵�毂� 鞐嗢潓
须岇偓电� 2025雲� 4鞗� 雮橃姢雼� 靸侅灔鞚措澕電� 欷戩殧頃� 鞚挫爼響滊ゼ 雼劚頄堨溂氅�, 2025雲� 7鞗旉箤歆� SSi Mantra 3鞐� 雽�頃� FDA De Novo 鞁犾箔靹滊ゼ 鞝滌稖頃� 瓿勴殟鞚措┌, 2025雲� 毵愱箤歆� EU CE 鞚胳 鞀轨澑霃� 於旍頃橁碃 鞛堨姷雼堧嫟.
SS Innovations (NASDAQ : SSII) a annonc茅 de solides r茅sultats financiers pour le 1er trimestre 2025 avec un chiffre d'affaires trimestriel record de 5,1 millions de dollars, en hausse de 40,8 % par rapport 脿 l'ann茅e pr茅c茅dente. Cette croissance a 茅t茅 port茅e par l'augmentation des ventes de leur syst猫me chirurgical robotis茅 SSi Mantra 3. Les points cl茅s comprennent :
  • 15 nouvelles installations de syst猫mes (augmentation de 66,7 % en glissement annuel)
  • La marge brute s'est 茅tendue 脿 21,23 %
  • La perte nette s'est am茅lior茅e 脿 5,7 millions de dollars (0,03 $ par action) contre 9,8 millions (0,06 $ par action) au 1er trimestre 2024
  • La base install茅e cumul茅e a atteint 78 unit茅s avec 3 568 interventions chirurgicales r茅alis茅es au total
  • Une tr茅sorerie de 15,9 millions de dollars sans dette 脿 long terme
L'entreprise a franchi une 茅tape importante avec son introduction au Nasdaq en avril 2025 et pr茅voit de soumettre une demande De Novo 脿 la FDA pour le SSi Mantra 3 d'ici juillet 2025, tout en poursuivant l'obtention de la certification CE pour l'UE d'ici la fin de 2025.
SS Innovations (NASDAQ: SSII) meldete starke Finanzergebnisse f眉r das 1. Quartal 2025 mit einem rekordverd盲chtigen Quartalsumsatz von 5,1 Millionen US-Dollar, was einem Anstieg von 40,8 % im Jahresvergleich entspricht. Das Wachstum wurde durch erh枚hte Verk盲ufe ihres chirurgischen Robotersystems SSi Mantra 3 angetrieben. Wichtige Highlights umfassen:
  • 15 neue Systeminstallationen (66,7 % Steigerung im Jahresvergleich)
  • Bruttomarge ausgeweitet auf 21,23 %
  • Nettoverlust verbessert auf 5,7 Millionen US-Dollar (0,03 US-Dollar pro Aktie) gegen眉ber 9,8 Millionen US-Dollar (0,06 US-Dollar pro Aktie) im 1. Quartal 2024
  • Kumulativer installierter Bestand erreichte 78 Einheiten mit insgesamt 3.568 durchgef眉hrten Operationen
  • Barmittelbestand von 15,9 Millionen US-Dollar bei null langfristigen Schulden
Das Unternehmen erreichte einen bedeutenden Meilenstein mit der Notierung an der Nasdaq im April 2025 und plant, bis Juli 2025 einen De Novo FDA-Antrag f眉r SSi Mantra 3 einzureichen, w盲hrend es gleichzeitig die CE-Kennzeichnung f眉r die EU bis Ende 2025 anstrebt.
Positive
  • Record quarterly revenue of $5.1M, up 40.8% YoY
  • 67% increase in system installations (15 vs 9 in Q1 2024)
  • Improved gross margin to 21.23% from 20.02%
  • Reduced net loss by 41.8% to $5.7M from $9.8M
  • Strong cash position of $15.9M with zero long-term debt
  • Successful Nasdaq uplisting in April 2025
  • New regulatory approvals in Philippines and Ukraine
  • 302.7% growth in instrument sales revenue
Negative
  • Still operating at a significant net loss of $5.7M
  • Relatively low gross margin at 21.23% despite improvement
  • FDA and EU approvals still pending for major market expansion

Insights

SS Innovations delivered 41% revenue growth with expanded installations, reduced losses, and progressing FDA plans, indicating positive momentum.

SS Innovations has posted a 40.8% year-over-year revenue increase to $5.1 million in Q1 2025, primarily driven by a 28.8% growth in system sales of their SSi Mantra 3 surgical robotic system. This performance demonstrates robust commercial traction, with quarterly installations jumping 66.7% from 9 to 15 units compared to Q1 2024.

What's particularly encouraging is the revenue diversification pattern. While system sales remain the primary growth driver, instrument sales surged by 302.7% and warranty revenue grew by an impressive 1,202.3%, albeit from a small base. This suggests the developing annuity revenue streams typical of successful medical device business models 鈥� where the initial system placement creates recurring revenue opportunities through consumables and service contracts.

The company is also demonstrating operational improvement with gross margin expanding by 121 basis points to 21.23%, attributed to reduced raw material costs. The net loss narrowed significantly from $9.8 million to $5.7 million, representing a 41.8% reduction in losses while maintaining growth investments.

The cumulative installed base has more than tripled year-over-year to 78 systems, with total procedures reaching 3,568 鈥� a 264% increase. This acceleration in procedure volume outpacing installed base growth indicates improving utilization rates, a critical metric for robotic surgery adoption.

From a regulatory standpoint, SS Innovations is targeting a July 2025 De Novo FDA application, which would open access to the lucrative US market. Combined with EU market pursuit and recent approvals in two additional countries, the company is executing a methodical global expansion strategy backed by a $15.9 million cash position and zero long-term debt.

The Nasdaq uplisting completed in April represents a significant milestone that should improve liquidity and institutional investor access. While still operating at a loss, the company appears to be on a path toward improving unit economics as scale increases.

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales
On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3听听

FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- (the 鈥淐ompany鈥� or 鈥淪S Innovations鈥�) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025.听听 The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the Securities and Exchange Commission on May 14, 2025.

First Quarter 2025 Overview

  • Revenue increased 40.8% to $5.1 million from $3.6 million in the first quarter of 2024.
  • Gross margin expanded 121 basis points to 21.23% from 20.02% in the first quarter of 2024.
  • Gross profit rose 49.3% to $1.1 million from $0.7 million in the first quarter of 2024.
  • Net loss of $5.7 million, or $(0.03) per diluted share, compared to net loss of $9.8 million, or $(0.06) per diluted share, in the first quarter of 2024.
  • SSi Mantra surgical robotic system installations totaled 15, up 66.7% from 9 installations in the first quarter of 2024.

As of March 31, 2025

  • Long-term debt of $0.
  • Cash and cash equivalents totaled $15.9 million, excluding restricted cash.
  • SSi Mantra cumulative installed base totaled 78 and cumulative surgeries reached 3,568.

Subsequent Events

  • On April 25, 2025, the Company鈥檚 common stock uplisted to The Nasdaq Capital Market庐.

CEO Commentary
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, 鈥淚n the first quarter of 2025, we achieved record quarterly revenue of $5.1 million, up 40.8% from $3.6 million in the first quarter of 2024, driven by higher unit sales of our innovative, cutting-edge SSi Mantra 3 surgical robotic system to leading healthcare facilities in India and abroad. Our gross margin also improved during the quarter, primarily reflecting a reduction in raw material prices. With an expanding installed base and growing utilization of SSi Mantra 3 by medical professionals globally, SS Innovations is well positioned for continued robust organic growth during the remainder of the year.鈥�

Dr. Srivastava continued, 鈥淎fter quarter end, we uplisted to Nasdaq, an exciting milestone that symbolizes a new chapter of global expansion for the Company. We intend to widen our presence beyond the seven countries where our SSi Mantra surgical robotic system has been cleared to market, with a focus on pursuing approval in the European Union and United States. We plan to submit a De Novo application for SSi Mantra to the U.S. Food and Drug Administration by the end of July 2025 for multiple indications and continue along the pathway towards a European Union CE Mark decision as soon as late 2025. Our vision is to decentralize and democratize robotic surgery by deploying our cost-effective, gold-standard SSi Mantra 3 devices across the globe for the benefit of a wider range of patients in need.鈥�

Select Business Highlights in First Quarter 2025

  • The SSi Mantra 3 surgical robotic system enabled the world鈥檚 first ever robotic cardiac telesurgery.
  • The Company鈥檚 state-of-the-art mobile telesurgery unit debuted in India with the aim of improving remote surgical access.
  • The SSi Mantra 3 received medical device regulatory approvals in the Philippines and Ukraine.

Revenue Breakdown and Summary of Installations / Surgeries

CategoryQ1 2024Q1 2025VariancePercentage
System sales$3,494,759$4,502,482$1,007,72328.8%
Instrument sales听118,515听477,208听358,693302.7%
Warranty sales听9,407听122,504听113,0971,202.3%
Lease income听15,012听18,416听3,40422.7%
Total revenue$3,637,693$5,120,610$1,482,91740.8%
听听听听听
SSi Mantra installations听9听15听667%
Cumulative installed base1听24听78听54225 %
听听听听听
SSi Mantra surgeries听361听787听426118%
Cumulative surgeries1听981听3,568听2,587264%
听听听听听听听听听
1 at period end听听听听听听听听


About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company鈥檚 product range includes its proprietary 鈥淪Si Mantra鈥� surgical robotic system and its comprehensive suite of 鈥淪Si Mudra鈥� surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company鈥檚 website at or for more information and updates.

About the SSi Mantra
The SSi Mantra Surgical Robotic System is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward-Looking Statements 鈥� Safe Harbor
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渨ill,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渟eek,鈥� 鈥渄esigned,鈥� 鈥減otential,鈥� 鈥渇orecast,鈥� 鈥渢arget,鈥� 鈥渙bjective,鈥� 鈥済oal,鈥� or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International鈥檚 future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group听听听听听听听听
Kalle Ahl, CFA听听听听听听听听听听听听听听听听
T: (303) 953-9878听听听听听听听听

Devin Sullivan, Managing Director
T: (212) 836-9608

Media Contact:

T: (212) 739-0300


听
SS INNOVATIONS INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
听
听听听As of听
听听听March 31,
2025		听听December 31,
2024		听
听听听听听听听听
ASSETS听听听听听听听
Current Assets:听听听听听听听
Cash and cash equivalents听听$15,873,217听听$466,500听
Restricted cash听听听5,886,589听听听5,838,508听
Accounts receivable, net听听听3,962,202听听听4,466,047听
Inventory, net听听听14,295,141听听听10,206,898听
Prepaids and other current assets听听听7,602,794听听听6,438,338听
Total Current Assets听听听47,619,943听听听27,416,291听
听听听听听听听听听听
Non- Current Assets:听听听听听听听听听
Property, plant, and equipment, net听听听7,044,307听听听5,385,955听
Right of use asset听听听2,629,225听听听2,623,880听
Accounts receivable, net听听听2,818,043听听听3,299,032听
Restricted cash- Non current听听听318,982听听听318,527听
Prepaids and other non current assets听听听3,026,461听听听3,341,528听
Total Non-Current Assets听听听15,837,018听听听14,968,922听
Total Assets听听$63,456,961听听$42,385,213听
听听听听听听听听听听
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY听听听听听听听听听
Current Liabilities听听听听听听听听听
Bank overdraft facility听听$7,682,411听听$7,994,906听
Notes payable听听听-听听听7,450,000听
Current portion of operating lease liabilities听听听368,309听听听409,518听
Accounts payable听听听3,641,410听听听2,312,382听
Deferred revenue听听听1,871,275听听听1,278,602听
Accrued expenses & other current liabilities听听听1,433,308听听听1,884,814听
Total Current Liabilities听听听14,996,713听听听21,330,222听
听听听听听听听听听听
Non- Current Liabilities听听听听听听听听听
Operating lease liabilities, less current portion听听听2,402,653听听听2,349,118听
Deferred Revenue- Non Current听听听5,405,227听听听5,173,953听
Other non current liabilities听听听98,078听听听74,817听
Total Non-Current Liabilities听听听7,905,958听听听7,597,888听
Total Liabilities听听$22,902,671听听$28,928,110听
听听听听听听听听听听
Stockholders鈥� equity:听听听听听听听听听
Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share;听听1,000 shares issued and outstanding as of March 31, 2025 and December 31, 2024听听听1听听听1听
Common stock,听听250,000,000 shares authorized, $0.0001 par value, 193,556,177 shares and 171,579,284 shares issued and outstanding as of March 31, 2025 and December 31, 2024 respectively听听听19,354听听听17,157听
Accumulated other comprehensive income (loss)听听听(726,911)听听(749,625)
Additional paid in capital听听听89,705,829听听听56,952,200听
Capital reserve听听听899,917听听听899,917听
Accumulated deficit听听听(49,343,900)听听(43,662,547)
Total stockholders鈥� equity听听听40,554,290听听听13,457,103听
Total liabilities and stockholders鈥� equity听听$63,456,961听听$42,385,213听


听
SS INNOVATIONS INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
听
听听听For The Three months ended听
听听听March 31,
2025		听听March 31,
2024		听
听听听听听听听听
REVENUES听听听听听听听
System sales听听听4,502,482听听听3,494,759听
Instruments sale听听听477,208听听听118,515听
Warranty sale听听听122,504听听听9,407听
Lease income听听听18,416听听听15,012听
Total revenue听听$5,120,610听听$3,637,693听
Cost of revenue听听听(4,033,402)听听(2,909,511)
听听听听听听听听听听
GROSS PROFIT听听听1,087,208听听听728,182听
听听听听听听听听听听
OPERATING EXPENSES:听听听听听听听听听
Research & development expense听听听1,010,095听听听527,991听
Stock compensation expense听听听2,379,212听听听7,108,750听
Depreciation and amortization expense听听听208,882听听听80,101听
Selling, general and administrative expense听听听3,410,872听听听2,843,659听
TOTAL OPERATING EXPENSES听听听7,009,061听听听10,560,501听
听听听听听听听听听听
Loss from operations听听听(5,921,853)听听(9,832,319)
听听听听听听听听听听
OTHER INCOME (EXPENSE):听听听听听听听听听
Interest Expense听听听(379,905)听听(190,088)
Interest and other income, net听听听620,405听听听180,654听
TOTAL OTHER INCOME (EXPENSE), NET听听听240,500听听听(9,434)
听听听听听听听听听听
LOSS BEFORE INCOME TAXES听听听(5,681,353)听听(9,841,753)
Income tax expense听听听-听听听-听
NET LOSS听听$(5,681,353)听$(9,841,753)
听听听听听听听听听听
Net loss per share - basic and diluted听听$(0.03)听$(0.06)
Weighted average- basic shares听听听178,836,342听听听170,729,490听
Weighted average- diluted shares听听听188,599,859听听听181,609,691听
听听听听听听听听听听
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS听听听听听听听听听
听听听听听听听听听听
NET LOSS听听$(5,681,353)听$(9,841,753)
听听听听听听听听听听
OTHER COMPREHENSIVE INCOME (LOSS)听听听听听听听听听
Foreign currency translation gain/(loss)听听听6,876听听听(79,314)
Retirement Benefit (net of tax)听听听15,838听听听8,507听
TOTAL COMPREHENSIVE LOSS听听$(5,658,639)听$(9,912,560)


听
SS INNOVATIONS INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
听
听听For The Three months ended听
听听March 31,
2025		听听March 31,
2024		听
Cash flows from operating activities:听听听听听听
听听听听听听听
Net loss听$(5,681,353)听$(9,841,753)
Adjustments to reconcile net loss to net cash used in operating activities:听听听听听听听听
Depreciation and amortization听听208,882听听听80,101听
Operating lease expense听听205,275听听听178,871听
Interest Expense听听155,015听听听283,868听
Interest and other income, net听听(140,928)听听(168,746)
(Reversal of) / Provision for credit loss reserve听听(422,711)听听389,330听
Stock compensation expense听听2,379,212听听听7,108,750听
听听听听听听听听听
Changes in operating assets and liabilities:听听听听听听听听
Accounts receivable, net听听1,275,750听听听(3,186,108)
Inventory, net听听(5,082,673)听听(1,326,859)
Deferred revenue听听823,947听听听2,290,417听
Prepaids and other assets听听(1,003,604)听听56,511听
Accounts payable听听1,329,028听听听926,083听
Accrued expenses & other liabilities听听48,331听听听705,455听
Operating lease payment听听(197,545)听听(167,838)
Net cash used in operating activities听听(6,103,374)听听(2,671,918)
听听听听听听听听听
Cash flows from investing activities:听听听听听听听听
Purchase of property, plant and equipment听听(872,804)听听(127,255)
Net cash used in investing activities听听(872,804)听听(127,255)
听听听听听听听听听
Cash flows from financing activities:听听听听听听听听
Proceeds from bank overdraft facility (net)听听(312,495)听听188,259听
Proceeds from issuance of convertible notes to principal shareholder听听28,000,000听听听1,000,000听
Proceeds from issuance of convertible notes to other investors听听-听听听1,450,000听
Repayment of convertible notes to principal shareholder, including interest听听(4,212,637)听听-听
Repayment of convertible notes to other investors, including interest听听(1,068,849)听听-听
Net cash provided by financing activities听听22,406,019听听听2,638,259听
听听听听听听听听听
Net change in cash听听15,429,841听听听(160,914)
Effect of exchange rate on cash听听25,412听听听(31,351)
Cash and cash equivalents at the beginning of the period听听6,623,535听听听7,087,845听
Cash and cash equivalents at end of the period听$22,078,788听听$6,895,580听
听听听听听听听听听
Supplemental disclosure of cash flow information:听听听听听听听听
Conversion of convertible notes into common stock, including interest听$30,645,360听听$-听
Transfer of systems from inventory to property, plant and equipment听$994,430听听$1,422,880听

FAQ

What were SSII's Q1 2025 financial results?

SS Innovations reported Q1 2025 revenue of $5.1M (up 40.8% YoY), gross margin of 21.23%, and net loss of $5.7M ($0.03 per share). The company installed 15 new SSi Mantra systems and maintained $15.9M in cash with no long-term debt.

How many SSi Mantra surgical systems has SSII installed to date?

As of March 31, 2025, SS Innovations has a cumulative installed base of 78 SSi Mantra systems, which have performed 3,568 surgeries in total.

When will SSII submit FDA application for SSi Mantra 3?

SS Innovations plans to submit a De Novo application to the FDA for SSi Mantra 3 by the end of July 2025.

What was SSII's revenue growth in Q1 2025?

SSII's revenue grew 40.8% year-over-year to $5.1 million in Q1 2025, compared to $3.6 million in Q1 2024.

How much cash does SSII have on hand?

As of March 31, 2025, SS Innovations had $15.9 million in cash and cash equivalents, excluding restricted cash, with zero long-term debt.
Stock SSII logo
SS Innovations

NASDAQ:SSII

SSII Rankings

#2961 Ranked by Market Cap
N/A Ranked by Dividends
#41 Top Loser

SSII Latest News

Jul 10, 2025
SS Innovations Announces Completion of World鈥檚 First Robotic Telesurgery for Weight Loss with the Company鈥檚 SSi Mantra 3 Surgical Robotic System
Jun 16, 2025
SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company鈥檚 SSi Mantra 3 Surgical Robotic System
Jun 2, 2025
SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025
May 27, 2025
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
May 8, 2025
SS Innovations to Submit De Novo Application to the FDA for the SSi Mantra 3 Surgical Robotic System for Multiple Indications

SSII Latest SEC Filings

Jul 10, 2025
[8-K] SS Innovations International Inc. Reports Material Event
Jun 30, 2025
[Form 4] SS Innovations International Inc. Insider Trading Activity
Jun 30, 2025
[Form 4/A] SS Innovations International Inc. Amended Insider Trading Activity

SSII Stock Data

1.00B
33.17M
77.88%
Medical Devices
Surgical & Medical Instruments & Apparatus
India
FORT LAUDERDALE

Related Articles

Continue reading with these related stories

View All Latest News